# Association Between Clinical Frailty and Antibiotic Resistance Among Older Patients with Fever in the Emergency Department

**Authors:** Ji Yeon Lim, Dong Hoon Lee, Ho Sub Chung, Yunhyung Choi, Yoon Hee Choi, Keon Kim, Ki-Hun Hong, Sung Jin Bae

PMC · DOI: 10.3390/antibiotics15030296 · Antibiotics · 2026-03-14

## TL;DR

Older emergency department patients with fever who are frail are more likely to have antibiotic-resistant infections and worse outcomes.

## Contribution

This study is the first to show a strong link between frailty and antibiotic resistance in older ED patients with fever.

## Key findings

- Frail patients had a 30% rate of antibiotic-resistant isolates compared to 10.7% in robust patients.
- Frailty was independently associated with resistant infections (adjusted OR 2.84).
- Frail patients had higher ICU admission and mortality rates than robust patients.

## Abstract

Background: Frailty may predispose older adults to antibiotic-resistant infections; however, evidence in emergency department (ED) patients with fever remains limited. Methods: We conducted a retrospective multicenter cohort study of 544 ED patients aged ≥65 years with fever (tympanic temperature ≥ 37.5 °C) between August and October 2023. The cohort included 234 men and 310 women. Frailty was assessed using the Clinical Frailty Scale (CFS) and categorized as robust (CFS 1–3), pre-frail (CFS 4–5), or frail (CFS 6–9). ED-initiated microbiological cultures were obtained in 329/544 (60.5%) patients. The primary outcome was the detection of antibiotic-resistant isolates among culture-tested patients. Results: Among culture-tested patients (n = 329), antibiotic-resistant isolates were detected in 65/329 (19.8%), with a graded increase across frailty strata: robust 13/121 (10.7%), pre-frail 16/88 (18.2%), and frail 36/120 (30.0%). In multivariable logistic regression restricted to culture-tested patients, frailty was independently associated with resistant infection (adjusted OR 2.84, 95% CI 1.15–7.04, p = 0.024). Frail patients also experienced greater therapeutic complexity, including higher rates of antibiotic regimen modification (68.1% vs. 54.5%) and longer antibiotic duration (median, 11 vs. 8 days), as well as worse clinical outcomes, including higher ICU admission (37.7% vs. 17.8%) and in-hospital mortality (7.2% vs. 1.8%) compared with robust patients. Conclusions: Frailty is independently associated with antibiotic-resistant infections in older ED patients with fever. Integrating frailty assessment into ED protocols can enhance risk stratification, inform empirical antibiotic selection, and antimicrobial stewardship strategies.

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** Bacteremia (MESH:D016470), ED (MESH:D004630), hypotension (MESH:D007022), coagulase-negative Staphylococci (MESH:D064726), lung cancer (MESH:D008175), bacterial infections (MESH:D001424), infection (MESH:D007239), injury to (MESH:D014947), CRE (MESH:D004756), terminally ill (MESH:D007153), chronic obstructive pulmonary disease (MESH:D029424), CFS (MESH:D000073496), diabetes mellitus (MESH:D003920), VRE (MESH:D060467), gut microbiome dysbiosis (MESH:D064806), impaired immune function (MESH:D007154), cardiovascular disease (MESH:D002318), bloodstream infection (MESH:D018805), shock (MESH:D012769), dead (MESH:D001926), chronic kidney disease (MESH:D051436), gut microbiome (MESH:C536735), nutritional deterioration (MESH:D009748), inflammation (MESH:D007249), immune dysregulation (OMIM:614878), Infectious diseases (MESH:D003141), congestive heart failure (MESH:D006333), Fever (MESH:D005334), MR (MESH:D008944), MRSA (MESH:D013203)
- **Chemicals:** oxygen (MESH:D010100), Lactic acid (MESH:D019344), meropenem (MESH:D000077731), methicillin (MESH:D008712), carbapenem (MESH:D015780), ceftriaxone (MESH:D002443), Vancomycin (MESH:D014640), piperacillin-tazobactam (MESH:D000077725), creatinine (MESH:D003404)
- **Species:** gut metagenome (species) [taxon 749906], Enterobacterales (order) [taxon 91347], Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606], Pseudomonas aeruginosa (species) [taxon 287], Enterobacteriaceae (enterobacteria, family) [taxon 543], Acinetobacter baumannii (species) [taxon 470]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024625/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024625/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024625/full.md

---
Source: https://tomesphere.com/paper/PMC13024625